IJCS | Volume 32, Nº2, March/April 2019

101 1. Biasucci LM, Della Bona R. Prognostic Biomarkers in ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2011;57(1):37-9. 2. Piegas LS, Timerman A, Feitosa GS, Nicolau JC, Mattos LAP, Andrade MD, et al. V Diretriz da Sociedade Brasileira de Cardiologia sobre Tratamento do Infarto Agudo do Miocárdio com Supradesnível do Segmento ST. Arq Bras Cardiol. 2015;105(2):1-105. 3. Scirica BM, Libby, P, Morrow DA. ST-Elevation Myocardial Infarction: Pathophysiology and Clinical Evolution in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11 th ed. Amsterdan:Elsevier; 2019. P.1095-122. 1095-122 4. Ortolani P, A. Marzocchi, C. Marrozzini, Palmerini T, Saia F, Taglieri N, et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J. 2008;29(10):1241-9 5. Celik T, Iyisoy A, Kursaklioglu H, Turhan H, Kilic S, Kose S, et al. The impact of admission C-reactive protein levels on the development of poor myocardialperfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron Artery Dis. 2005;16(5):293-9. 6. Ribeiro DRP, Ramos AM, Vieira PL, Menti E, Bordin Jr. OL, de Souza PAL, et al. High-Sensitivity C-Reactive Protein as a Predictor of Cardiovascular Events after ST-Elevation Myocardial Infarction Arq Bras Cardiol. 2014;103(1):69–75. 7. Parenica J, Kala P, Pavkova MG, Tomandl J, Spinar J, Littnerova S ET al. Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMIpatients - Multiple biomarkers prospective cohort study. Int J Cardiol. 2016;211:96-104. 8. Damman P., Beijk MAM, Kuijt WJ, Verouden NJ, van Gelove N, Henriques JP. Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2011;57(1):29-36. 9. Correia LC, Esteves JP. C-Reactive protein and outcomes in acutecoronary syndromes: a systematic review and meta-analysis. Arq Bras Cardiol.2011;97(1):76-85. 10. Milano SS, Moura Júnior OV, Bordin AAS, Marques GL. C-reactive Protein is a Predictor of Mortality in ST-segment Elevation Acute Myocardial Infarction. Int J Cardiol Sci. 2019;32(2)118-124. 11. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20(4):457-64. 12. Steg P, Dabbous OH, FeldmanLJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation.2004;109(4):494-9. 13. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatmet of infracting myocardium early II Trial Substudy. Circulation. 2000;102(17):2031-7. References Spineti Biomarkers and mortality in ST-segment elevation myocardial infarction Int J Cardiovasc Sci. 2019;32(2)100-101 Editorial CRP to usual prognostic score systems in STEMI, such as GRACE 12 and TIMI Risk 13 scores. Another major issue is the absence of new treatments directly addressing hs- CRP in STEMI. 3 Despite these biases and limitations, we believe the study has some merits. The findings suggest that hs-CRP levels can be used as ameasure of inflammatory response to myocardial ischemia after STEMI, which could lead to a more personalized prognosis and therapy to improve the outcome in this population. Prospective and larger cohort studies are needed to confirm these findings and to stablish a cut point for a wider clinical use of this tool. Randomized controlled trials are needed to establish the effectiveness of new treatment regimens guided by biomarkers in STEMI. This is an open-access article distributed under the terms of the Creative Commons Attribution License